FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										

0.5

hours per response:

	Check this box if no longer subject to Section 16. Form 4 or Form 5										
l	obligations may continue. See										
	Instruction 1(b).										

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					0	or Sect	ion 30(h)	of the	inves	stment C	company Act	of 1940							
1. Name and Address of Reporting Person* SNODGRASS H. RALPH					2. Issuer Name and Ticker or Trading Symbol <u>VistaGen Therapeutics, Inc.</u> [VSTA]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
												_ I _	Off:	give title		Other (sp			
(Last)	(F	irst)	(Middle)		3.	Date o	of Earliest	Trans	saction	n (Month	n/Day/Year)		_	X Officer (give title Other (s below)					
C/O VISTAGEN THERAPEUTICS, INC.					09	09/02/2015								PRES./CHIEF SCIENTIFIC OFFICER					
343 ALLERTON AVENUE																			
(Street) SOUTH FRANCE	()	A	94080		4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																
		Та	ble I - Non	-Deriv	ativ	∕e Se	curities	s Ac	quir	ed, Di	sposed o	of, or Be	neficially	Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				action Day/Year)		2A. Deemed Execution Dat if any (Month/Day/Ye		, Tı	3. Transaction Code (Instr. 8) 4. Securities Acquired (A) of (D) (Instr. 3, 4)			5. Amoun Securities Beneficia Owned Fo Reported	s For ally (D) ollowing (I) (I		Direct Indirect B	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								С	Code V Amount		(A) (D)	Price	Transacti (Instr. 3 a	ion(s)		"	1130.4)		
			Table II - D								posed of converti			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Co	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Cod	ode	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amount or Number of Shares	unt (Instr. 4) per		n(s)			
Warrant for Common Stock	\$9.25	09/02/2015			A		150,000		09/0	2/2015	09/02/2020	Common Stock	150,000	\$0	150,00	0	I	By Trust ⁽¹⁾	

Explanation of Responses:

1. Held by the H. Ralph Snodgrass Living Trust, dated 10/2/2008

/s/ Jerrold Dotson, Attorney-in

Fac

** Signature of Reporting Person Date

09/03/2015

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.